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Combined therapy with gonadotropin-releasing hormone (GnRH) analogue and growth hormone (GH)
has been used to increase the height of adolescents who are not GH deficient and who have normally timed
puberty. Its use, however, is still controversial. For 2 years simultaneously, we treated eight healthy girls
with very low predicted adult height (PAH < 145 cm) who were entering into normally timed puberty.
The GnRH analogue triptorelin pamoate (Decapeptyl, 100 +g/kg intramuscularly every 4 weeks) and GH
(0.1 IU/kg/day subcutaneously, 6 days/week) were administered. The mean chronologic age (CA) of our
patients was 11.01 ( 0.95 years, and mean bone age (BA) was 12.25 ( 1.13 years. With a height of 131.50
( 5.83 cm (–2.37 (  0.35 SD below the mean) and PAH of 140.87 (  3.53 cm, they were all in Tanner stage
2–3 of puberty (except one patient in stage 4). In all cases, GH and thyroid hormone deficiency were ruled
out before the study began. Height and BA were measured immediately after discontinuation of therapy.
PAH was determined before and at the end of therapy. Combined treatment resulted in a 4.13 (  1.19 cm
increase in PAH (p < 0.01). Height increased significantly to 142.66 (  3.54 cm at the end of treatment
(p < 0.01). Height standard deviation score for CA increased from –2.37 (  0.35 to –2.32 (  0.67, showing no
significant improvement (p = 0.5). Height age (HA)/BA ratio and BA/CA ratio both demonstrated
significant growth during the treatment (p < 0.03 and p < 0.01, respectively), whereas HA/CA ratio did
not improve significantly (p < 0.32). During treatment, puberty was completely suppressed in all cases.
Combination therapy with GnRH analogue and GH resulted in significant improvement in height and
PAH during therapy. Additional, and perhaps more long-term, studies are required to show whether this
kind of treatment is effective in improving final adult height. The cost–benefit of such therapies should
also be taken into account.
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Subjects with short stature and normal growth hormone
(GH) secretion, termed “idiopathic short stature”, comprise
© 2006 Elsevier. All rights reserved.
a very heterogeneous group of patients, including a large
number of children with constitutional growth delay,
familial short stature, or both. Clinicians have used a
combination of GH and gonadotropin-releasing hormone
(GnRH) analogue in children with idiopathic short
stature [1].
Increased secretion of GH plays an important role in the
pubertal growth spurt. The effect of GH on final height can
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be influenced negatively by the rapid bone maturation that
is seen in puberty [2]. On the other hand, GnRH analogues
slow bone-age (BA) progression and rapid growth, and
have the potential to extend the time available for pubertal
growth [3]. Therefore, there is increasing interest in the role
of postponing puberty as a component of growth-promoting
therapy.
Many research groups have investigated the effects of
various doses and lengths of treatment on adult height. For
instance, in cases of idiopathic short stature, GH alone has
been used with controversial results [4–6]. GnRH analogues
alone also have been used in the same condition, still with
controversial results [7,8].
We evaluated the effect of combined therapy with GH
and GnRH analogue on eight girls with idiopathic short
stature and normally timed puberty.
PATIENTS AND METHODS
Eight short girls with a mean chronologic age (CA) of
11.02 ( 0.95 years and a mean BA of 12.25 ( 1.13 years were
studied. All were comparatively short in stature, with a
mean height of 131.50 (  5.83 cm (–2.37 (  0.35 SD below
the mean) and mean predicted adult height (PAH) of
140.87 ( 3.53 cm. All were in early puberty: Tanner stage
2–3 for breasts and pubic hair (except one subject in Tanner
stage 4).
All girls were healthy and well nourished without any
identifiable endocrine, chromosomal or systemic illness; or
any history of perinatal insult, intrauterine growth
retardation; or other possible causal medical conditions.
The clinical characteristics of our subjects are depicted in
Table 1.
GH deficiency was ruled out by a normal GH response
to administration of L-DOPA and propranolol on two
separate occasions. Complete blood cell count, routine blood
chemistries, and thyroid function tests were also normal in
all subjects before the beginning of treatment.
This study was approved by our university ethics
committee. Informed consent was obtained from the subjects
and their parents after discussing both the auxologic and
endocrine findings on each child, as well as explaining the
probable effects of treatment.
Subjects received GH at a dose of 0.1 IU/kg/day given
subcutaneously for 6 days per week (Novo Nordisk A/S,
Bagsværd, Denmark) and the GnRH analogue triptorelin
pamoate (Decapeptyl, Beaufour Ipsen, Paris, France) at a
dose of 100 +g/kg, administered intramuscularly, every 4
weeks. Both medications were started simultaneously, and
all patients were treated for 24 months.
Height was measured with a stadiometer by the same
examiner, and the mean of three measurements was
recorded at the beginning, at 3-month intervals, and at the
termination of therapy. BAs were measured before and
after the treatment by the same radiologist using the
method of Greulich and Pyle [9]. PAHs were calculated
by the method of Bayley and Pinneau [10]. Routine
chemistries and complete blood cell counts were obtained
at each 4-month visit.
Data are expressed as the mean ( SD unless otherwise
stated. Because the number of cases was limited, statistical
analysis was performed using nonparametric tests
(Wilcoxon matched-pairs signed-ranks test).
Table 1. Clinical characteristics of patients at entry into the study
Patient no. CA (yr) BA (yr) Height (cm) Pubertal status (Tanner) PAH (cm)
Breast Pubic hair
1 10.17 11 124 3 2 132.5
2 10 11.5 126 3 3 143.7
3 11 12 130 3 3 141
4 10.5 11 128 3 3 143
5 10.25 12 130 3 3 141
6 11.75 13 136 3 3 141
7 12 13.5 138 3 3 142
8 12.5 14 140 4 4 142.75
Mean ( SD 11.02 ( 0.95 12.25 ( 1.13 131.50 ( 5.83 – – 140.87 ( 3.53
BA = bone age; CA =  chronologic age; PAH = predicted adult height.
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RESULTS
Combined treatment with the GnRH analogue and GH
resulted in an interruption of pubertal development in all
patients. Height increased significantly from 131.50 (  5.83
cm at the beginning to 142.66 (  3.54 cm at the end of
treatment (p < 0.01). BA and PAH increased from 12.25 (
1.13 years to 13.97 ( 1.00 years and from 140.87 ( 3.53 cm to
145.66 (  2.34 cm, respectively; the latter was statistically
significant (p < 0.01).
Auxologic data of the patients are given in Table 2.
Whereas height age (HA)/BA ratio and BA/CA ratio
both increased significantly during treatment (p < 0.03 and
p < 0.01, respectively), HA/CA ratio did not change
significantly.
HA was 9.19 ( 1.05 years at the beginning of treatment
and reached 11.19 (  0.62 (Table 3). Height, expressed as
SD score for CA (Ht SDS-CA), increased from –2.37 ( 0.35 to
–2.32 (  0.67 at the end of treatment, but showing no
prominent growth (p = 0.57) (Table 3).
Height after treatment was 142.66 ( 3.54 cm; this value
was 1.79 ( 2.21 cm greater than the PAH before the start of
treatment (140.87 (  3.52 cm) (p < 0.05) (Figure) and was
below the PAH after treatment (145.66 ( 2.34 cm).
DISCUSSION
GH therapy is now used for treating short stature in subjects
not deficient in GH, but the administration of this therapy is
controversial. One reason is that short subjects who are not
deficient in GH are a heterogeneous group, including patients
with different clinical and hormonal characteristics. The
effect of long-term GH treatment on short children not
deficient in GH has been reported by some researchers. Hintz
et al treated 121 short children, who were not deficient in GH,
with GH for 2–10 years [4]. In 80 children, adult height was
increased to a level above the PAH and above the adult
height of untreated historical control children This agrees
with the reports by Finkelstein et al [5] and Leschek et al [6].
Table 2. Auxologic data of patients before and after therapy
Before treatment After treatment Statistical significance
BA (yr) 12.25 ( 1.13 13.97 ( 1.00 Insignificant
Height (cm) 131.50 ( 5.83 142.66 ( 3.54 p < 0.01*
PAH (cm) 140.87 ( 3.53 145.66 ( 2.34 p < 0.01*
Ht SDS-CA –2.37 ( 0.35 –2.32 ( 0.67 Insignificant
HA/BA ratio 0.74 ( 0.02 0.80 ( 0.05 p < 0.03*
HA/CA ratio 0.83 ( 0.04 0.86 ( 0.05 Insignificant
BA/CA ratio 1.12 ( 0.03 1.07 ( 0.03 p < 0.01*
BA = bone age; CA = chronologic age; HA = height age; PAH =  predicted adult height. *Values are the mean ( SD. p < 0.05 was considered significant.
Table 3. Chronologic age, height age, and SD score for chronologic age of patients before and after therapy
Patient Chronologic age Height age SD score for CA
no. Before treatment After treatment Before treatment After treatment Before treatment After treatment
1 10.17 12.17 7.75 9.75 –3.02 –2.97
2 10 12 8.25 11.25 –2.31 –1.33
3 11 13 9 11.25 –2.37 –2.26
4 10.5 12.5 8.5 11.25 –2.61 –2.05
5 10.25 12.5 9 11.25 –1.90 –1.51
6 11.75 13.75 10 11.75 –2.39 –2.45
7 12 14 10.25 11.25 –1.97 –3.26
8 12.5 14.5 10.75 11.75 –2.41 –2.71
Mean ( SD 11.02 ( 0.95 13.05 ( 0.93 9.19 ( 1.05 11.19 ( 0.62 –2.37 ( 0.35 –2.32 ( 0.67
CA = chronologic age.
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On the other hand, Hindmarsh and Brook suggested that
the small increment in final height does not justify the
widespread use of GH for short normal children [11].
In order to delay or slow pubertal development, the
addition of GnRH analogues to GH therapy in peripubertal
subjects, who are not deficient in GH, is justified. GnRH
analogues are widely used for treating central precocious
puberty. These agents suppress gonadotropins and gonadal
steroid secretions, resulting in the slowing of bone
maturation [1,2,12].
For idiopathic short stature, combined treatment of
GnRH analogues and GH has been performed, leading to
conflicting results for adult height. Municchi et al found in
their study that the pubertal delay induced by long-term
use of GnRH analogues increased the predicted adult height
of adolescence with short stature and normally timed
puberty [8]; the same result was achieved by Kamp et al
[13]. Saggese et al also found combined therapy to be useful
in increasing the height prognosis of subjects without GH
deficiency and normal-onset puberty [14], but in another
study conducted by Balducci et al, despite the significant
improvement in predicted height during treatment, this
form of therapy did not result in an increase in adult stature
[12]. Lanes and Gunczler also reported that the final height
of patients did not improve significantly compared with
PAH before treatment [15].
In this study, eight short-stature normal girls with PAH
of less than 145 cm were treated with GnRH analogue and
GH. GH was administered in daily doses of 0.1 IU/kg 6
days per week; this is equal to the amount used in some
other studies [12,15]. We used Decapeptyl (100 +g/kg
intramuscularly every 4 weeks) instead of Leuprolide, which
was used in higher doses by others [12,15]. In the present
study, low doses of GnRH analogue were adequate to
suppress pubertal development in all patients; because the
patients were in the early stages of puberty, higher doses
would have been redundant.
Combined treatment resulted in a significant increase in
PAH, similar to the findings of Saggese et al [14], with
comparable duration of treatment, number of patients, and
pubertal status. Ht-SDS-CA did not show a prominent rise,
similar to findings of Saggese et al [14], and Lanes and
Gunczler [15]. Height after treatment was significantly
greater than PAH before treatment; Pasquino et al also
came to the same conclusion while treating patients for a
longer period and with higher doses [16].
In the present study, we did not measure final adult
height. At discontinuation of therapy, in some patients,
the growth plates were still not completely calcified, so
height at this stage was not final adult height. BA/CA, HA/
BA, and HA/CA ratios are three predictors of final adult
height. HA/BA ratio improved significantly after treatment
(p < 0.03). The same result was achieved by Balducci et al
[12] and Saggese et al [14]. BA/CA decreased at the end of
treatment, similarly to another study [14], implying the
effectiveness of combined treatment on delaying bone
maturation.
To summarize, combined treatment of eight normal
girls with idiopathic short stature and normally timed
puberty, using GH and GnRH analogue for 2 years, resulted
in suppression of puberty, delay of bone maturation, and
increase in height and PAH.
Possible disadvantages of postponing puberty using
GnRH analogue include weight gain and psychosocial
consequences, such as withdrawn behavior, anxiety,
depression, and social problems [2]. In the present study,
weight gain was the only side effect noted in all treated
patients.
Considering the economic and ethical costs, these
therapies should be limited and individualized to very
short subjects in whom a gain of even a few centimeters
could be considered worthwhile. Additional long-term
investigations are required to evaluate the precise effect of
combined treatment on final adult height in individuals
with idiopathic short stature.
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